70,662 DexCom, Inc. $DXCM Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 13.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 609,412 shares of the medical device company’s stock after acquiring an additional 70,662 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in DexCom were worth $52,586,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Interchange Capital Partners LLC grew its position in DexCom by 9.7% in the 3rd quarter. Interchange Capital Partners LLC now owns 4,865 shares of the medical device company’s stock valued at $421,000 after purchasing an additional 429 shares during the period. Financial Network Wealth Advisors LLC raised its holdings in DexCom by 154.5% during the third quarter. Financial Network Wealth Advisors LLC now owns 588 shares of the medical device company’s stock worth $51,000 after buying an additional 357 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in DexCom by 15.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,316 shares of the medical device company’s stock worth $1,414,000 after buying an additional 2,197 shares during the last quarter. BOKF NA raised its holdings in DexCom by 78.7% during the third quarter. BOKF NA now owns 19,202 shares of the medical device company’s stock worth $1,657,000 after buying an additional 8,454 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. raised its holdings in DexCom by 89.4% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 572 shares of the medical device company’s stock worth $49,000 after buying an additional 270 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

DexCom Stock Performance

Shares of DXCM stock opened at $82.29 on Friday. The firm has a 50-day moving average of $85.82 and a 200-day moving average of $74.65. The company has a market cap of $31.05 billion, a P/E ratio of 32.27, a P/E/G ratio of 1.34 and a beta of 1.48. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. DexCom had a net margin of 19.42% and a return on equity of 36.96%. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period last year, the firm earned $0.61 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 3,638 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of DexCom stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the transaction, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. This represents a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 24,822 shares of company stock worth $2,090,833 in the last ninety days. 0.28% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DXCM. Benchmark raised their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Wells Fargo & Company upped their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Monday, August 3rd. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $92.91.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.